StockData
InMed Pharmaceuticals Inc. logo

InMed Pharmaceuticals Inc. (MTRI) stock

MTRINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as INM
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 4/30
$17.50−2.37 (-11.93%)

Close on Nov 17, 2026Market cap $96.14MP/E –Yield –

InMed Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

InMed Pharmaceuticals's operating income for the twelve months ending Sep 30, 2023 was -$6.97M. For fiscal 2023 it was -$7.95M.

Annual operating income

PeriodPeriod endValueChange
FY2023Jun 30, 2023-$7.95M–
FY2022Jun 30, 2022-$18.60M–
FY2021Jun 30, 2021-$10.20M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2024CQ3 2023Sep 30, 2023-$2.54M–
Q4 FY2023CQ2 2023Jun 30, 2023-$338.39K–
Q3 FY2023CQ1 2023Mar 31, 2023-$2.00M–
Q2 FY2023CQ4 2022Dec 31, 2022-$2.10M–
Q1 FY2023CQ3 2022Sep 30, 2022-$3.51M–
Q4 FY2022CQ2 2022Jun 30, 2022-$7.87M–
Q3 FY2022CQ1 2022Mar 31, 2022-$3.48M–
Q2 FY2022CQ4 2021Dec 31, 2021-$4.28M–
Q1 FY2022CQ3 2021Sep 30, 2021-$2.97M–
Q4 FY2021CQ2 2021Jun 30, 2021-$3.26M–
Q3 FY2021CQ1 2021Mar 31, 2021-$3.10M–
Q2 FY2021CQ4 2020Dec 31, 2020-$2.24M–

More InMed Pharmaceuticals figures

See a number that looks wrong?